SCHEMBL25551937

SCHEMBL25551937

COC(=O)c1ncc(CNC(=O)OC(C)(C)C)c(-c2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CKS1B P61024 4/20 0.49
▸ SKP1 P63208 4/20 0.49
▸ SKP2 Q13309 4/20 0.49
▸ ALDH1A1 P00352 2/20 0.47
▸ KDM4A O75164 1/20 0.41
▸ ACACB O00763 2/20 0.40
▸ ACACA Q13085 2/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ TRPV1 Q8NER1 2/20 0.39
▸ NAMPT P43490 1/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ KCNA5 P22460 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30036979 1.00 CKS1B (0.49) CKS1BSKP1SKP2ALDH1A1KDM4A
SCHEMBL25551904 0.91 CKS1B (0.51) CKS1BSKP1SKP2KDM4AACACB
SCHEMBL25551932 0.78 ALDH1A1 (0.56) ALDH1A1GABRA5MEN1GAAKMT2A
SCHEMBL30036948 0.78 ALDH1A1 (0.56) ALDH1A1GABRA5MEN1GAAKMT2A
SCHEMBL25551910 0.78 ALDH1A1 (0.56) ALDH1A1GABRA5MEN1GAAKMT2A
SCHEMBL27612489 0.73 CKS1B (0.46) CKS1BSKP1SKP2KDM4AACACB
SCHEMBL17133422 0.73 CKS1B (0.51) CKS1BSKP1SKP2KDM4A
SCHEMBL30037572 0.73 ALDH1A1 (0.49) ALDH1A1GABRA5MEN1GAAKMT2A
SCHEMBL25551926 0.73 ALDH1A1 (0.49) ALDH1A1GABRA5MEN1GAAKMT2A
SCHEMBL17133442 0.73 CKS1B (0.51) CKS1BSKP1SKP2KDM4AACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-05-25 — — US disclosed
EP-4110765-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE Board of Regents, The University of Texas System (US) 2023-01-04 — — EP disclosed
CN-115515940-A Inhibitors of receptor interacting protein kinase I for the treatment of disease 德州大学系统董事会 2022-12-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159508-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 CKS1B 348/4885SKP1 455/4885SKP2 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback